Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J‐ACNES): A multicenter, open‐label, randomized, controlled study

• DOI: 10.1002/joa3.12084
• Publication Date: 2018-08-31T12:18:05Z
• Authors: Kohei Ishibashi; Yoshinobu Eishi; Nobuhiro Tahara; Masanori Asakura; Naka Sakamoto; Kazufumi Nakamura; Yoichi Takaya; Tomohisa Nakamura; Yoshikazu Yazaki; Tetsuo Yamaguchi; Koko Asakura; Toshihisa Anzai; Teruo Noguchi; Satoshi Yasuda; Fumio Terasaki; Toshimitsu Hamasaki; Kengo Kusano
• Keywords: Open label; Cardiac sarcoidosis

Abstract Background Cardiac sarcoidosis ( CS ) is a noncaseating granulomatous disease of unknown etiology. Lifelong immunosuppressive therapy, most frequently using corticosteroids, standard therapy to control hypersensitivity immune reactions and prevent inflammation. However, it sometimes causes various systemic adverse effects requires dose escalation. Thus, additional may be required for the treatment this disease. Recently, Propionibacterium acnes P. was reported as one etiologic agents , indicating that antibacterial drugs ABD effective . The objective study investigate effect treatment, in addition corticosteroid patients with Methods Japanese Antibacterial Drug Management Sarcoidosis (J‐ ACNES trial designed prospective, multicenter, randomized, open‐label, controlled clinical trial. will randomized receive either plus group) or (standard group). primary endpoint change total standardized uptake value at 6 months vs baseline fluorine‐18 fluorodeoxyglucose positron emission tomography computed tomography. Secondary endpoints include efficacy, prognosis, safety. Results results are currently under investigation. Conclusion J‐ first prospective assessing benefit safety Our findings improve reduces recurrence inflammation elucidates mechanism sarcoidosis.